Skip to main content

Table 3 Numbers of patients receiving Gaucher disease specific treatments

From: The European Gaucher Alliance: a survey of member patient organisations’ activities, healthcare environments and concerns

Member association's country Imiglucerase Velaglucerase alfa Eliglustat tartrate Miglustat Taliglucerase alfa Other* Total
Austria 11 5 4 1    21
Belgium 22 3   1    26
Bosnia & Herzegovina 3 1 0     4
Bulgaria 13       13
Canada 60 13 13 11 2   99
Czech Republic 21 6   2    29
Denmark 11 5      16
Estonia 3       3
Finland 6 2   1    9
Germany 230 61 9   1   301
Greece 57 6 3 6    72
Israel 80 160 10   60 5 315
Italy 113 35   10    158
Jordan 16 1      17
Latvia 2       2
Lithuania 8       8
Macedonia 4       4
Norway 5 8      13
Romania 55 1 2     58
Russia 258 6 40     304
Serbia 13   6   8   27
Slovenia 13 4      17
South Africa 48    3 5   56
Spain 80 50 4 30 5   169
Sweden 37 6   3    46
UK & RoI 112 93 2 7 5 1 220
Ukraine 36       36
TOTAL 1317 466 93 75 86 6 2043
% of total 64 23 5 4 4 0.3  
  1. *Other treatments: Israel: oral enzyme replacement therapy (PRX-112) in clinical trial [Protalix, Carmiel, Israel], UK & RoI: 1 alglucerase.